271 related articles for article (PubMed ID: 20671118)
1. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.
Fox CP; Haigh TA; Taylor GS; Long HM; Lee SP; Shannon-Lowe C; O'Connor S; Bollard CM; Iqbal J; Chan WC; Rickinson AB; Bell AI; Rowe M
Blood; 2010 Nov; 116(19):3695-704. PubMed ID: 20671118
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features.
Jeon YK; Kim JH; Sung JY; Han JH; Ko YH;
Hum Pathol; 2015 Jul; 46(7):981-90. PubMed ID: 25907865
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
5. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas.
Xu ZG; Iwatsuki K; Oyama N; Ohtsuka M; Satoh M; Kikuchi S; Akiba H; Kaneko F
Br J Cancer; 2001 Apr; 84(7):920-5. PubMed ID: 11286472
[TBL] [Abstract][Full Text] [Related]
6. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.
Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N
J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563
[TBL] [Abstract][Full Text] [Related]
7. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
[TBL] [Abstract][Full Text] [Related]
8. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.
Chiang AK; Tao Q; Srivastava G; Ho FC
Int J Cancer; 1996 Nov; 68(3):285-90. PubMed ID: 8903467
[TBL] [Abstract][Full Text] [Related]
9. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a multiepitope plasmid DNA encoding T and B lymphocyte epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a vaccine in mice.
Li W; Chen Q; Lin Q; Lv Y; Feng J; Liu J; Xu W; Chen S; Zhu X; Zhang L
Protein Pept Lett; 2013 Oct; 20(10):1136-43. PubMed ID: 23688153
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach.
Hue SS; Oon ML; Wang S; Tan SY; Ng SB
Pathology; 2020 Jan; 52(1):111-127. PubMed ID: 31767131
[TBL] [Abstract][Full Text] [Related]
12. Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis.
Saleem A; Natkunam Y
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098335
[No Abstract] [Full Text] [Related]
13. Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients.
Greijer AE; Stevens SJ; Verkuijlen SA; Juwana H; Fleig SC; Verschuuren EA; Hepkema BG; Cornelissen JJ; Brooimans RA; Verdonck LF; Middeldorp JM
Clin Dev Immunol; 2012; 2012():543085. PubMed ID: 23346186
[TBL] [Abstract][Full Text] [Related]
14. Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines.
Sun L; Hao Y; Wang Z; Zeng Y
Viruses; 2018 Mar; 10(4):. PubMed ID: 29570629
[TBL] [Abstract][Full Text] [Related]
15. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
Eom HS; Choi BK; Lee Y; Lee H; Yun T; Kim YH; Lee JJ; Kwon BS
J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947
[TBL] [Abstract][Full Text] [Related]
16. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
[TBL] [Abstract][Full Text] [Related]
17. EBV-NK cells interactions and lymphoproliferative disorders.
Kanegane H; Yachie A; Miyawaki T; Tosato G
Leuk Lymphoma; 1998 May; 29(5-6):491-8. PubMed ID: 9643562
[TBL] [Abstract][Full Text] [Related]
18. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
[TBL] [Abstract][Full Text] [Related]
19. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
Lin N; Ku W; Song Y; Zhu J; Lu Z
Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
[TBL] [Abstract][Full Text] [Related]
20. Generation of Epstein-Barr Virus Antigen-Specific T Cell Receptors Recognizing Immunodominant Epitopes of LMP1, LMP2A, and EBNA3C for Immunotherapy.
Dudaniec K; Westendorf K; Nössner E; Uckert W
Hum Gene Ther; 2021 Sep; 32(17-18):919-935. PubMed ID: 33798008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
